keyword
https://read.qxmd.com/read/38505074/differential-response-to-roflumilast-in-patients-with-chronic-obstructive-pulmonary-disease-real-world-evidence
#1
JOURNAL ARTICLE
Hyun Woo Lee, Jiyu Sun, Hyo-Jin Lee, Jung-Kyu Lee, Tae Yeon Park, Eun Young Heo, Chin Kook Rhee, Deog Kyeom Kim
BACKGROUND: Roflumilast is effective in reducing acute exacerbation in patients with chronic obstructive pulmonary disease (COPD) at high risk of severe exacerbation. Clinical traits related to the benefits of roflumilast need to be evaluated in patients with COPD. METHODS: A longitudinal observational study in patients newly diagnosed with COPD was conducted using claims data from the Health Insurance Review and Assessment Service in South Korea from 2012-2020 after a 2-year washout period...
February 29, 2024: Journal of Thoracic Disease
https://read.qxmd.com/read/38505044/a-comparison-of-gold-2019-and-2023-recommendations-to-contemporaneous-real-world-inhaler-treatment-patterns-for-chronic-obstructive-pulmonary-disease-management-in-singapore
#2
JOURNAL ARTICLE
Rayan Alsuwaigh, Anthony Yii, Chee Hong Loh, Xiaomeng Xu, Priti Bahety, Aldo A Navarro Rojas, Dominique Milea, Augustine Tee
BACKGROUND: In 2019 and 2023, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) provided updated strategies for modifying the therapy of patients with chronic obstructive pulmonary disease (COPD) and high exacerbation risk. A key update since the 2019 guidelines recommends considering blood eosinophil count to guide decisions on inhaled corticosteroid (ICS) treatment. To evaluate the potential impact of these updated recommendations, this study aimed to assess how extensively future practice would diverge from contemporaneous prescribing practices at a single center in Singapore, assuming adherence to the 2019 and 2023 GOLD guidelines...
February 29, 2024: Journal of Thoracic Disease
https://read.qxmd.com/read/38424530/effects-of-triple-therapy-on-disease-burden-in-patients-of-gold-groups-c-and-d-results-from-the-observational-copd-cohort-cosyconet
#3
JOURNAL ARTICLE
Jennifer A Zader, Rudolf A Jörres, Imke Mayer, Peter Alter, Robert Bals, Henrik Watz, Pontus Mertsch, Klaus F Rabe, Felix Herth, Franziska C Trudzinski, Tobias Welte, Hans-Ulrich Kauczor, Jürgen Behr, Julia Walter, Claus F Vogelmeier, Kathrin Kahnert
BACKGROUND: Randomized controlled trials described beneficial effects of inhaled triple therapy (LABA/LAMA/ICS) in patients with chronic obstructive pulmonary disease (COPD) and high risk of exacerbations. We studied whether such effects were also detectable under continuous treatment in a retrospective observational setting. METHODS: Data from baseline and 18-month follow-up of the COPD cohort COSYCONET were used, including patients categorized as GOLD groups C/D at both visits (n = 258)...
March 1, 2024: BMC Pulmonary Medicine
https://read.qxmd.com/read/38383272/multidisciplinary-management-of-patients-with-chronic-obstructive-pulmonary-disease-and-cardiovascular-disease
#4
JOURNAL ARTICLE
Javier de Miguel-Díez, Julio Núñez Villota, Salud Santos Pérez, Nicolás Manito Lorite, Bernardino Alcázar Navarrete, Juan Francisco Delgado Jiménez, Juan José Soler-Cataluña, Domingo Pascual Figal, Patricia Sobradillo Ecenarro, Juan José Gómez Doblas
Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) frequently coexist, increasing the prevalence of both entities and impacting on symptoms and prognosis. CVD should be suspected in patients with COPD who have high/very high risk scores on validated scales, frequent exacerbations, precordial pain, disproportionate dyspnea, or palpitations. They should be referred to cardiology if they have palpitations of unknown cause or angina pain. COPD should be suspected in patients with CVD if they have recurrent bronchitis, cough and expectoration, or disproportionate dyspnea...
February 1, 2024: Archivos de Bronconeumología
https://read.qxmd.com/read/38329243/-medication-management-of-copd
#5
JOURNAL ARTICLE
Marina Gueçamburu, Maeva Zysman
MEDICATION MANAGEMENT OF COPD. The management of chronic obstructive pulmonary disease (COPD) is based on drug and non-drug measures. Inhaled therapies are the major issues including the use of short-acting bronchodilators for respiratory symptoms. If symptoms are daily, such as disabling dyspnea or frequent exacerbations, daily treatment with a long-acting bronchodilator is proposed: anti-muscarinic (LAMA) or β2-agonist (LABA). If there is no improvement, escalation to dual and then triple therapy is proposed...
January 2024: La Revue du Praticien
https://read.qxmd.com/read/38326272/treatment-pathways-economic-burden-and-clinical-outcomes-in-new-users-of-inhaled-corticosteroid-long-acting-b-2-agonist-dual-therapy-with-chronic-obstructive-pulmonary-disease-in-a-primary-care-setting-in-england-a-retrospective-cohort-study
#6
JOURNAL ARTICLE
Alexandrosz Czira, Victoria Banks, Gema Requena, Robert Wood, Theo Tritton, Rosie Wild, Chris Compton, Afisi Ismaila
OBJECTIVE: Management of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroid/long-acting β2 -agonist (ICS/LABA) improves lung function and health status and reduces COPD exacerbation risk versus monotherapy. This study described treatment use, healthcare resource utilisation (HCRU), healthcare costs and outcomes following initiation of single-device ICS/LABA as initial maintenance therapy (IMT). DESIGN: Retrospective cohort study. SETTING: Primary care, England...
February 7, 2024: BMJ Open
https://read.qxmd.com/read/38321329/cardiovascular-events-with-the-use-of-long-acting-muscarinic-receptor-antagonists-an-analysis-of-the-faers-database-2020-2023
#7
JOURNAL ARTICLE
Maria Gabriella Matera, Luigino Calzetta, Paola Rogliani, Nicola Hanania, Mario Cazzola
PURPOSE: This study aimed to examine reports of cardiovascular adverse events (CV AEs) observed in the real-world during treatment with aclidinium, tiotropium, glycopyrronium, and umeclidinium alone or in combination with a LABA and, in the context of triple therapy, with the addition of an ICS, and submitted to the food and drug administration adverse event reporting system (FAERS). METHODS: A retrospective disproportionality analysis was conducted utilizing CV AE reports submitted to the FAERS from January 2020 to 30 September 2023...
February 6, 2024: Lung
https://read.qxmd.com/read/38310193/outcomes-of-patients-with-copd-treated-with-ics-laba-before-and-after-initiation-of-single-inhaler-triple-therapy-with-fluticasone-furoate-umeclidinium-vilanterol-ff-umec-vi
#8
JOURNAL ARTICLE
Meredith McCormack, Rosirene Paczkowski, Noelle N Gronroos, Stephen G Noorduyn, Lydia Lee, Phani Veeranki, Mary G Johnson, Emmeline Igboekwe, Kristin Kahle-Wrobleski, Reynold Panettieri
INTRODUCTION: Triple therapy (fluticasone furoate/umeclidinium/vilanterol; FF/UMEC/VI) has been shown to improve symptoms and reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations. This real-world study compared exacerbation rates and healthcare resource utilization (HCRU) before and after initiation of FF/UMEC/VI in patients with COPD previously treated with inhaled corticosteroid (ICS)/long-acting β2 -agonist (LABA). METHODS: This retrospective cohort study included commercial and Medicare Advantage with Part D administrative claims data from September 01, 2016, to March 31, 2020, of patients diagnosed with COPD...
February 4, 2024: Advances in Therapy
https://read.qxmd.com/read/38288811/insights-from-overviewing-selective-international-guidelines-for-pediatric-asthma
#9
JOURNAL ARTICLE
Kam Lun Ellis Hon, Daniel K K Ng, Wa Keung Chiu, Alexander K C Leung
BACKGROUND: Asthma is a chronic atopic and inflammatory bronchial disease characterized by recurring symptoms and, episodic reversible bronchial obstruction and easily triggered bronchospasms. Asthma often begins in childhood. International guidelines are widely accepted and implemented; however, there are similarities and differences in the management approaches. There is no national guideline in many cities in Asia. This review aims to provide a practical perspective on current recommendations in the management of childhood asthma, specifically in the following aspects: diagnosis, classification of severity, treatment options, and asthma control, and to provide physicians with up-to-date information for the management of asthma...
January 29, 2024: Current Pediatric Reviews
https://read.qxmd.com/read/38269030/cardiovascular-events-according-to-inhaler-therapy-and-comorbidities-in-chronic-obstructive-pulmonary-disease
#10
JOURNAL ARTICLE
Eun Kyung Kim, Eunyoung Lee, Ji Eun Park, Jae Seung Lee, Hye Sook Choi, Bumhee Park, Seung Soo Sheen, Kwang Joo Park, Chin Kook Rhee, Sang Yeub Lee, Kwang Ha Yoo, Joo Hun Park
BACKGROUND: COPD coexists with many concurrent comorbidities. Cardiovascular complications are deemed to be major causes of death in COPD. Although inhaler therapy is the main therapeutic intervention in COPD, cardiovascular events accompanying inhaler therapy require further investigation. Therefore, this study aimed to investigate new development of cardiovascular events according to each inhaler therapy and comorbidities. METHODS: This study analyzed COPD patients (age ≥ 40 years, N = 199,772) from the Health Insurance Review and Assessment Service (HIRA) database in Korea...
2024: International Journal of Chronic Obstructive Pulmonary Disease
https://read.qxmd.com/read/38263115/clinical-outcomes-of-long-term-inhaled-combination-therapies-in-patients-with-bronchiectasis-and-airflow-obstruction
#11
JOURNAL ARTICLE
Hyo Jin Lee, Jung-Kyu Lee, Tae Yeon Park, Eun Young Heo, Deog Kyeom Kim, Hyun Woo Lee
BACKGROUND AND OBJECTIVES: Few studies have reported which inhaled combination therapy, either bronchodilators and/or inhaled corticosteroids (ICSs), is beneficial in patients with bronchiectasis and airflow obstruction. Our study compared the efficacy and safety among different inhaled combination therapies in patients with bronchiectasis and airflow obstruction. METHODS: Our retrospective study analyzed the patients with forced expiratory volume in 1 s (FEV1 )/forced vital capacity < 0...
January 23, 2024: BMC Pulmonary Medicine
https://read.qxmd.com/read/38184091/clinical-characteristics-and-healthcare-resource-utilization-in-patients-with-chronic-obstructive-pulmonary-disease-in-hong-kong
#12
JOURNAL ARTICLE
Fanny Wai San Ko, Xiaomeng Xu, Clementine Chau, Aldo Navarro, David Hui Shu Cheong, Dominique Milea
OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a significant cause of mortality, with its prevalence projected to rise in Asia. The primary objective of this study was to describe clinical characteristics, maintenance treatment, and healthcare resource utilization (HCRU) among patients with COPD in Hong Kong. Secondary objectives were to assess patient demographics and clinical characteristics by eosinophil (EOS) levels, and compare the demographics, clinical characteristics, and treatment patterns of patients on multiple-inhaler triple therapy (MITT)...
January 4, 2024: Respiratory Medicine
https://read.qxmd.com/read/38112909/delphi-consensus-on-clinical-applications-of-gold-2023-recommendations-in-copd-management-how-aligned-are-recommendations-with-clinical-practice
#13
JOURNAL ARTICLE
Antonio Anzueto, Mark Cohen, Andres L Echazarreta, Gehan Elassal, Irma Godoy, Rafael Paramo, Abdullah Sayiner, Carlos A Torres-Duque, Sudeep Acharya, Bhumika Aggarwal, Hakan Erkus, Gur Levy
INTRODUCTION: The objective of this Delphi study was to understand and assess the level of consensus among respiratory experts on the clinical application of GOLD 2023 recommendations in management of patients with chronic obstructive pulmonary disease (COPD). METHODS: The study comprised two online surveys and a participant meeting with 34 respiratory experts from 16 countries. Responses of 73 questions were recorded using a Likert scale ranging from 0 (disagreement) to 9 (agreement)...
December 19, 2023: Pulmonary Therapy
https://read.qxmd.com/read/38054551/inhaled-corticosteroids-with-combination-inhaled-long-acting-beta2-agonists-and-long-acting-muscarinic-antagonists-for-chronic-obstructive-pulmonary-disease
#14
REVIEW
Wouter H van Geffen, Daniel J Tan, Julia Ae Walters, E Haydn Walters
BACKGROUND: Management of chronic obstructive pulmonary disease (COPD) commonly involves a combination of long-acting bronchodilators including beta2-agonists (LABA) and muscarinic antagonists (LAMA). LABA and LAMA bronchodilators are now available in single-combination inhalers. In individuals with persistent symptoms or frequent exacerbations, inhaled corticosteroids (ICS) are also used with combination LABA and LAMA inhalers. However, the benefits and risks of adding ICS to combination LABA/LAMA inhalers as a triple therapy remain unclear...
December 6, 2023: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/38032494/overuse-of-long-acting-%C3%AE-2-agonist-inhaled-corticosteroids-in-patients-with-chronic-obstructive-pulmonary-disease-time-to-rethink-prescribing-patterns
#15
REVIEW
Stephen A Brunton, D Kyle Hogarth
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality globally. In the major revision of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 report, the scientific committee concluded that the use of long-acting β2 -agonist/inhaled corticosteroids (LABA/ICS) is not encouraged in patients with COPD. However, current prescribing patterns reveal significant use of LABA/ICS. In this paper, the evidence behind the current practice and the latest treatment recommendations is reviewed...
November 2023: Postgraduate Medicine
https://read.qxmd.com/read/38018090/the-future-exacerbation-and-mortality-of-different-inhalation-therapies-among-patients-with-chronic-obstructive-pulmonary-disease-in-various-gold-groups-a-focus-on-the-gold-2017-and-gold-2023-reports
#16
MULTICENTER STUDY
Qing Song, Wei Cheng, Cong Liu, Xueshan Li, Ling Lin, Yating Peng, Yuqin Zeng, Rong Yi, Yi Liu, Xin Li, Yan Chen, Shan Cai, Ping Chen
BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 report revised the combined assessment, merged the C and D groups into the E group, and revised the initial inhalation therapy recommendation. OBJECTIVES: This study aimed to analyze the future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease (COPD) in various groups based on the GOLD 2017 and GOLD 2023 reports...
2023: Therapeutic Advances in Respiratory Disease
https://read.qxmd.com/read/38009437/rational-use-of-inhaled-corticosteroids-for-the-treatment-of-copd-a-plain-language-summary
#17
REVIEW
Amnon Ariel, Peter J Barnes, Tiago Maricoto, Miguel Román-Rodríguez, Andy Powell, Jennifer K Quint
Inhaled corticosteroids (ICS) are a type of medication delivered via an inhaler device that are commonly used in the treatment of asthma. ICS can also be used to treat chronic obstructive pulmonary disease (COPD), a progressive respiratory condition in which the lungs become worse over time. However, unlike in asthma, ICS are only effective in a small proportion of people with COPD. ICS can cause significant side effects in people with COPD, including pneumonia. Because of this, guidelines written by COPD experts recommend that ICS should largely be prescribed to people with COPD whose symptoms flare up frequently and become difficult to manage (episodes known as exacerbations)...
November 27, 2023: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/37936381/stepwise-management-of-copd-what-is-next-after-bronchodilation
#18
REVIEW
Marc Miravitlles, Kazuto Matsunaga, Michael Dreher
Inhaled bronchodilator therapy with long-acting muscarinic antagonists (LAMAs) and long-acting β2 -agonists (LABAs) in combination is currently the mainstay of treatment for chronic obstructive pulmonary disease (COPD). Treatment guidelines recommend the addition of inhaled corticosteroids (ICS) to LABA/LAMA only in patients with a history of frequent/severe exacerbations and high blood eosinophil counts, or in those with concomitant asthma. Despite this, real-world data suggest that clinicians are not adhering to this guidance and that ICS are frequently overused...
2023: Therapeutic Advances in Respiratory Disease
https://read.qxmd.com/read/37892832/risk-factors-for-recurrent-exacerbations-in-the-general-practitioner-based-swiss-chronic-obstructive-pulmonary-disease-copd-cohort
#19
JOURNAL ARTICLE
Nebal S Abu Hussein, Stephanie Giezendanner, Pascal Urwyler, Pierre-Olivier Bridevaux, Prashant N Chhajed, Thomas Geiser, Ladina Joos Zellweger, Malcolm Kohler, David Miedinger, Zahra Pasha, Robert Thurnheer, Christophe von Garnier, Joerg D Leuppi
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) often suffer from acute exacerbations. Our objective was to describe recurrent exacerbations in a GP-based Swiss COPD cohort and develop a statistical model for predicting exacerbation. METHODS: COPD cohort demographic and medical data were recorded for 24 months, by means of a questionnaire-based COPD cohort. The data were split into training (75%) and validation (25%) datasets. A negative binomial regression model was developed using the training dataset to predict the exacerbation rate within 1 year...
October 23, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37870866/development-and-validation-of-prediction-models-for-exacerbation-frequent-exacerbations-and-severe-exacerbations-of-chronic-obstructive-pulmonary-disease-a-registry-study-in-north-china
#20
JOURNAL ARTICLE
Yuyan Zhou, Siqi He, Wanying Wang, Xiaoyue Wang, Xiaoting Chen, Xiaoning Bu, Deshuai Li
In COPD patients, exacerbation has a detrimental influence on the quality of life, disease progression and socioeconomic burden. This study aimed to develop and validate models to predict exacerbation, frequent exacerbations and severe exacerbations in COPD patients. We conducted an observational prospective multicenter study. Clinical data of all outpatients with stable COPD were collected from Beijing Chaoyang Hospital and Beijing Renhe Hospital between January 2018 and December 2019. Patients were followed up for 1 year...
December 2023: COPD
keyword
keyword
114365
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.